title: First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study.
abstract: The purpose of this study was to study different doses for first-pass and equilibrium phase MRA of aortoiliac vessels with a superparamagnetic iron oxide (SPIO) intravascular MR contrast agent (SH U 555 C) after single i.v. bolus injection. Sixteen healthy volunteers were prospectively enrolled into this single-blind, placebo-controlled clinical trial. SHU 555 C was injected as an i.v. bolus at stepwise increased dose levels of 5, 10, 20 and 40 micromol Fe/kg bodyweight (b.w.) corresponding to injection volumes of 0.01, 0.02, 0.04 and 0.08 ml/kg b.w. Serial high-resolution three-dimensional MRA of the aortoiliac vessels was acquired during first-pass and equilibrium, at 6 min intervals up to 42 min after contrast application using a breath-hold three-dimensional FLASH sequence on a 1.5 T scanner. Intravascular enhancement was calculated within the abdominal aorta and the inferior vena cava and a statistical analysis for significant differences in vessel enhancement was performed during the bolus and equilibrium phases. The visibility of vessels was ranked and effects of potential artifacts on image quality were graded for each time point and dose group. SH U 555 C showed a dose-dependent intravascular enhancement during the observation period (42 min). The highest dose of 40 micromol Fe/kg b.w. revealed the highest image quality during first-pass and equilibrium phases. The intravascular enhancement in the aorta increased dose-dependently from 5 to 40 micromol kg b.w. during first-pass and equilibrium phases (p<0.05). Intravascular signal inhomogeneities were observed at lower doses and decreased with increasing doses. First-pass MRA was diagnostic at doses of 10, 20 and 40 micromol Fe/kg b.w. For equilibrium MRA, a dose of 40 micromol Fe/kg b.w. was considered to be diagnostic. SH U 555 C proved to be a contrast agent with a high T1-effect suitable for both first-pass MRA comparable to gadolinium-enhanced MRA and high resolution equilibrium MRA up to 42 min post-injection (p.i.).
authors.affiliation: Department of Clinical Radiology, Westfalian Wilhelms-University of Muenster, Muenster, Germany. Tombach@uni-muenster.de
authors.forename: Bernd
authors.initials: B
authors.lastname: Tombach
authors.forename: Peter
authors.initials: P
authors.lastname: Reimer
authors.forename: Christoph
authors.initials: C
authors.lastname: Bremer
authors.forename: Thomas
authors.initials: T
authors.lastname: Allkemper
authors.forename: Matthias
authors.initials: M
authors.lastname: Engelhardt
authors.forename: Marianne
authors.initials: M
authors.lastname: Mahler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Ebert
authors.forename: Walter
authors.initials: W
authors.lastname: Heindel
mesh_terms: D000328:Adult; D001011:Aorta / Q000033:anatomy & histology*; D003287:Contrast Media; D004305:Dose-Response Relationship, Drug; D005290:Ferric Compounds / Q000008:administration & dosage; D006801:Humans; D007083:Iliac Artery / Q000033:anatomy & histology*; D007089:Image Enhancement / Q000379:methods; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008297:Male; D016037:Single-Blind Method
chemical_list: D003287:Contrast Media; D005290:Ferric Compounds; C000499:ferric oxide